{"id":17008,"date":"2019-05-21T08:39:21","date_gmt":"2019-05-21T06:39:21","guid":{"rendered":"http:\/\/mabdesign.fr\/skymab-biotherapeutics-new-member\/"},"modified":"2023-10-17T10:48:28","modified_gmt":"2023-10-17T08:48:28","slug":"skymab-biotherapeutics-new-member","status":"publish","type":"post","link":"https:\/\/mabdesign.fr\/en\/skymab-biotherapeutics-new-member\/","title":{"rendered":"SKYMAB Biotherapeutics – new member"},"content":{"rendered":"

\"\" Skymab Biotherapeutics<\/strong> is a CEA* spin-off biotech company\u00a0committed to the design, engineering\u00a0and development of antibodies targeting\u00a0G Protein Coupled Receptors (GPCR) with a main focus in oncology.<\/p>\n

Skymab<\/strong> was founded by enthusiastic scientists and entrepreneurs, thrilled to combine the most valuable technical knowledge in antibody discovery with their challenging know how in GPCR to create innovative tailored antibodies that achieved specific therapeutic strategies.<\/p>\n

* French Atomic Agency (CEA), the most innovative public research organization in Europe according to a REUTERS ranking.<\/em><\/p>\n

To know more<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Skymab Biotherapeutics is a CEA spin-off biotech company\u00a0committed to the design, engineering\u00a0and development of antibodies targeting\u00a0G Protein Coupled Receptors (GPCR) with a main focus in oncology.<\/p>\n","protected":false},"author":1,"featured_media":862,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[33,36],"tags":[],"class_list":["post-17008","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-new-member","category-news"],"yoast_head":"\nSKYMAB Biotherapeutics - new member - MabDesign<\/title>\n<meta name=\"description\" content=\"Skymab Biotherapeutics is a CEA spin-off biotech company\u00a0committed to the design, engineering\u00a0and development of antibodies targeting\u00a0G Protein Coupled Receptors (GPCR) with a main focus in oncology.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/mabdesign.fr\/en\/skymab-biotherapeutics-new-member\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"SKYMAB Biotherapeutics - new member - MabDesign\" \/>\n<meta property=\"og:description\" content=\"Skymab Biotherapeutics is a CEA spin-off biotech company\u00a0committed to the design, engineering\u00a0and development of antibodies targeting\u00a0G Protein Coupled Receptors (GPCR) with a main focus in oncology.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/mabdesign.fr\/en\/skymab-biotherapeutics-new-member\/\" \/>\n<meta property=\"og:site_name\" content=\"MabDesign\" \/>\n<meta property=\"article:published_time\" content=\"2019-05-21T06:39:21+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-10-17T08:48:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/12\/LOGO-SMB-bleu.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"610\" \/>\n\t<meta property=\"og:image:height\" content=\"205\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"alexis.mathias@kairios.fr\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@MabDesign_fr\" \/>\n<meta name=\"twitter:site\" content=\"@MabDesign_fr\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"alexis.mathias@kairios.fr\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/mabdesign.fr\/en\/skymab-biotherapeutics-new-member\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/skymab-biotherapeutics-new-member\/\"},\"author\":{\"name\":\"alexis.mathias@kairios.fr\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/0a9d0510f7433c83f9e6974b2a9c0135\"},\"headline\":\"SKYMAB Biotherapeutics – new member\",\"datePublished\":\"2019-05-21T06:39:21+00:00\",\"dateModified\":\"2023-10-17T08:48:28+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/skymab-biotherapeutics-new-member\/\"},\"wordCount\":90,\"publisher\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/#organization\"},\"image\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/skymab-biotherapeutics-new-member\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/12\/LOGO-SMB-bleu.jpg\",\"articleSection\":[\"New member\",\"News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/mabdesign.fr\/en\/skymab-biotherapeutics-new-member\/\",\"url\":\"https:\/\/mabdesign.fr\/en\/skymab-biotherapeutics-new-member\/\",\"name\":\"SKYMAB Biotherapeutics - new member - MabDesign\",\"isPartOf\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/skymab-biotherapeutics-new-member\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/skymab-biotherapeutics-new-member\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/12\/LOGO-SMB-bleu.jpg\",\"datePublished\":\"2019-05-21T06:39:21+00:00\",\"dateModified\":\"2023-10-17T08:48:28+00:00\",\"description\":\"Skymab Biotherapeutics is a CEA spin-off biotech company\u00a0committed to the design, engineering\u00a0and development of antibodies targeting\u00a0G Protein Coupled Receptors (GPCR) with a main focus in oncology.\",\"breadcrumb\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/skymab-biotherapeutics-new-member\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/mabdesign.fr\/en\/skymab-biotherapeutics-new-member\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/mabdesign.fr\/en\/skymab-biotherapeutics-new-member\/#primaryimage\",\"url\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/12\/LOGO-SMB-bleu.jpg\",\"contentUrl\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/12\/LOGO-SMB-bleu.jpg\",\"width\":610,\"height\":205},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/mabdesign.fr\/en\/skymab-biotherapeutics-new-member\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/mabdesign.fr\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"SKYMAB Biotherapeutics – new member\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#website\",\"url\":\"https:\/\/mabdesign.fr\/en\/\",\"name\":\"Mabdesign\",\"description\":\"The Biotherapy Expert\",\"publisher\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/mabdesign.fr\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#organization\",\"name\":\"Mabdesign\",\"url\":\"https:\/\/mabdesign.fr\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/11\/logo-mabdesign.png\",\"contentUrl\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/11\/logo-mabdesign.png\",\"width\":786,\"height\":233,\"caption\":\"Mabdesign\"},\"image\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/x.com\/MabDesign_fr\",\"https:\/\/www.linkedin.com\/company\/mabdesign\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/0a9d0510f7433c83f9e6974b2a9c0135\",\"name\":\"alexis.mathias@kairios.fr\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/9f0235d3b23103c20120728bbe93c75ab83e508d42949114def0b4d989a03f94?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/9f0235d3b23103c20120728bbe93c75ab83e508d42949114def0b4d989a03f94?s=96&d=mm&r=g\",\"caption\":\"alexis.mathias@kairios.fr\"},\"sameAs\":[\"http:\/\/mabdesign.fr\"],\"url\":\"https:\/\/mabdesign.fr\/en\/author\/amathiasigtcreative-fr\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"SKYMAB Biotherapeutics - new member - MabDesign","description":"Skymab Biotherapeutics is a CEA spin-off biotech company\u00a0committed to the design, engineering\u00a0and development of antibodies targeting\u00a0G Protein Coupled Receptors (GPCR) with a main focus in oncology.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/mabdesign.fr\/en\/skymab-biotherapeutics-new-member\/","og_locale":"en_US","og_type":"article","og_title":"SKYMAB Biotherapeutics - new member - MabDesign","og_description":"Skymab Biotherapeutics is a CEA spin-off biotech company\u00a0committed to the design, engineering\u00a0and development of antibodies targeting\u00a0G Protein Coupled Receptors (GPCR) with a main focus in oncology.","og_url":"https:\/\/mabdesign.fr\/en\/skymab-biotherapeutics-new-member\/","og_site_name":"MabDesign","article_published_time":"2019-05-21T06:39:21+00:00","article_modified_time":"2023-10-17T08:48:28+00:00","og_image":[{"width":610,"height":205,"url":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/12\/LOGO-SMB-bleu.jpg","type":"image\/jpeg"}],"author":"alexis.mathias@kairios.fr","twitter_card":"summary_large_image","twitter_creator":"@MabDesign_fr","twitter_site":"@MabDesign_fr","twitter_misc":{"Written by":"alexis.mathias@kairios.fr"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/mabdesign.fr\/en\/skymab-biotherapeutics-new-member\/#article","isPartOf":{"@id":"https:\/\/mabdesign.fr\/en\/skymab-biotherapeutics-new-member\/"},"author":{"name":"alexis.mathias@kairios.fr","@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/0a9d0510f7433c83f9e6974b2a9c0135"},"headline":"SKYMAB Biotherapeutics – new member","datePublished":"2019-05-21T06:39:21+00:00","dateModified":"2023-10-17T08:48:28+00:00","mainEntityOfPage":{"@id":"https:\/\/mabdesign.fr\/en\/skymab-biotherapeutics-new-member\/"},"wordCount":90,"publisher":{"@id":"https:\/\/mabdesign.fr\/en\/#organization"},"image":{"@id":"https:\/\/mabdesign.fr\/en\/skymab-biotherapeutics-new-member\/#primaryimage"},"thumbnailUrl":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/12\/LOGO-SMB-bleu.jpg","articleSection":["New member","News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/mabdesign.fr\/en\/skymab-biotherapeutics-new-member\/","url":"https:\/\/mabdesign.fr\/en\/skymab-biotherapeutics-new-member\/","name":"SKYMAB Biotherapeutics - new member - MabDesign","isPartOf":{"@id":"https:\/\/mabdesign.fr\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/mabdesign.fr\/en\/skymab-biotherapeutics-new-member\/#primaryimage"},"image":{"@id":"https:\/\/mabdesign.fr\/en\/skymab-biotherapeutics-new-member\/#primaryimage"},"thumbnailUrl":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/12\/LOGO-SMB-bleu.jpg","datePublished":"2019-05-21T06:39:21+00:00","dateModified":"2023-10-17T08:48:28+00:00","description":"Skymab Biotherapeutics is a CEA spin-off biotech company\u00a0committed to the design, engineering\u00a0and development of antibodies targeting\u00a0G Protein Coupled Receptors (GPCR) with a main focus in oncology.","breadcrumb":{"@id":"https:\/\/mabdesign.fr\/en\/skymab-biotherapeutics-new-member\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/mabdesign.fr\/en\/skymab-biotherapeutics-new-member\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/mabdesign.fr\/en\/skymab-biotherapeutics-new-member\/#primaryimage","url":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/12\/LOGO-SMB-bleu.jpg","contentUrl":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/12\/LOGO-SMB-bleu.jpg","width":610,"height":205},{"@type":"BreadcrumbList","@id":"https:\/\/mabdesign.fr\/en\/skymab-biotherapeutics-new-member\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/mabdesign.fr\/en\/"},{"@type":"ListItem","position":2,"name":"SKYMAB Biotherapeutics – new member"}]},{"@type":"WebSite","@id":"https:\/\/mabdesign.fr\/en\/#website","url":"https:\/\/mabdesign.fr\/en\/","name":"Mabdesign","description":"The Biotherapy Expert","publisher":{"@id":"https:\/\/mabdesign.fr\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/mabdesign.fr\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/mabdesign.fr\/en\/#organization","name":"Mabdesign","url":"https:\/\/mabdesign.fr\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/logo\/image\/","url":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/11\/logo-mabdesign.png","contentUrl":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/11\/logo-mabdesign.png","width":786,"height":233,"caption":"Mabdesign"},"image":{"@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/MabDesign_fr","https:\/\/www.linkedin.com\/company\/mabdesign\/"]},{"@type":"Person","@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/0a9d0510f7433c83f9e6974b2a9c0135","name":"alexis.mathias@kairios.fr","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/9f0235d3b23103c20120728bbe93c75ab83e508d42949114def0b4d989a03f94?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/9f0235d3b23103c20120728bbe93c75ab83e508d42949114def0b4d989a03f94?s=96&d=mm&r=g","caption":"alexis.mathias@kairios.fr"},"sameAs":["http:\/\/mabdesign.fr"],"url":"https:\/\/mabdesign.fr\/en\/author\/amathiasigtcreative-fr\/"}]}},"_links":{"self":[{"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/posts\/17008","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/comments?post=17008"}],"version-history":[{"count":0,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/posts\/17008\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/media\/862"}],"wp:attachment":[{"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/media?parent=17008"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/categories?post=17008"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/tags?post=17008"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}